Los Angeles, CA, United States (4E) – A novel addiction treatment technology for alcoholics may also treat opioid or heroin dependence, which affects five million people in the U.S. and results to some 17,000 deaths yearly.
Kent Emry, CEO of BioCoRx, Inc. (OTCQB: BICX), discussed the entry of the company into the opioid addiction treatment market on Bloomberg Television’s Taking Stock with Pimm Fox on Friday.
Emry told Fox that Naltrexone is equally if not more effective in combating opioid addiction which includes heroin addiction.
BioCorRx, Inc. is a leader in addiction treatment and rehabilitation programs across the country. The California company’s Start Fresh Program treats addiction through the use of a proprietary implant containing the Food and Drug Administration-approved pharmaceutical, Naltrexone. The program combines the implant treatment with a custom-made life coaching program for alcohol addicts.
Actor Jeremy Miller, who joined Emry and Fox in the show, was a living testimony to the Start Fresh Program’s success.
“It saved my life,” Miller said of his experience of the implant, according to Globe Newswire. “It was like someone flicking off a light switch, that’s how drastic the feeling was. I went from obsessing about my next drink all day long, every moment of the day, to couldn’t have cared less whether I had a drink or not, inside of about three hours.”
“Not only has Jeremy beat his addiction, but as a well-known actor, he is using his voice to speak out and help others by spreading the word about this incredible program. We are very proud of him,” said Emry of the “Growing Pains” starrer.
BioCorRx’s foray in the $23 billion opioid addiction treatment industry will pit its SFP against opioid addiction drugs like Vivitrol, which the FDA approved in 2010 to treat and prevent relapse after patients with opioid dependence have undergone detoxification treatment. Vivitrol, manufactured by Alkermes, is an extended-release formulation of naltrexone administered by intramuscular injection once a month.
On April 3, the FDA announced that it approved Evzio (naloxone hydrochloride injection), a handheld device that can be used by family members or caregivers to deliver a single dose of naloxone for the emergency treatment of known or suspected opioid overdose. Evzio is manufactured by Richmond, Virginia-based kaleo Inc.
For the implant exclusively manufactured and distributed by BioCorRx, Naltrexone is time-released to the body to effectively curb a patient’s alcohol and opioid craving. The implant is placed subcutaneously or under the fatty layer of the skin just beneath the lower abdomen through a minimally-invasive, outpatient procedure. The procedure requires light sedation and takes around 15 to 20 minutes. It is performed by a licensed physician.
Patients who have undergone the procedure reported little to no discomfort from the insertion of the implant. Patients can walk in a clinic for the procedure and return to work within the same day.
Naltrexone is an opioid receptor antagonist that inhibits the brain’s “pleasure feelings,” according to BioCoRx. This prevents an addicted person to respond to the “endorphin” high brought on by opiates and alcohol.
BioCoRx’s formulation comes in the form of a single-administration, long-acting implant. The implant gradually releases Naltrexone into the bloodstream over the course of several months following the procedure for long-term drug and alcohol dependence management.
The implant takes effect as soon as it is introduced into the patient’s body. Some have reported feeling the immediate positive effects of Naltrexone within hours of administration. The implant may last up to 12 months, depending on the patient’s health and metabolism.
Naltrexone also comes in the form of oral 50 milligrams (mgs) tablets or injectibles. However, due to medical compliance reasons, most patients and primary care providers prefer the drug in implant form as a relapse is possible when a patient taking Naltrexone orally misses a dose.
“A patient whose craving becomes overwhelming can obtain euphoria simply by skipping a dose before resuming abuse,” BioCoRx said.
Possible side effects
According to Medline Plus, immediate side effects of using Naltrexone include stomach cramps and pain, vomiting, nausea, headaches, dizziness, loss of appetite, constipation, diarrhea, mood swings, rashes, fatigue and sleep disturbances. BioCorx notes that these symptoms manifest due to the body’s reaction to Naltroxone or the body’s detoxification process.
Slight inflammation may also appear on the part of the body where the implant has been embedded. This is completely normal and is nothing a topical medication (i.e. antibacterial ointment) cannot fix.
Solving opioid addiction
Battling America’s problem
The National Council on Alcoholism and Drug Dependence, Inc. (NCADD) reports that over 17.6 million people, or one in 12 adults, are afflicted with alcohol abuse or dependence. Opioid dependence affects five million people in the U.S. and results to around 17,000 deaths yearly, according to Medscape data.
Many alcohol dependents go in and out of rehab mainly because of the inadequacy of existing treatment methods. For example, Todd, a patient of BioCoRx advisor Dr. George Fallieras, said he has tried everything to treat his alcohol dependence.
“I praise the alcohol like you wouldn’t believe, long before detox,” Todd said in a recent episode of The Doctors. “I am excited about not drinking. I’ve never been this excited in my life,” he said.
Dr. Fallieras supervised Todd’s treatment and implant procedure. He also appeared on The Doctors along with Todd to explain how the Naltrexone implant works.
“It’s surreal. It’s mind-boggling. I haven’t had one craving whatsoever,” noted Todd on The Doctors, a week after undergoing the procedure.
Todd is working with Start Fresh Program life coach and spokesperson Miller, who is guiding him on his road to recovery. Miller is a former child star who rose to fame portraying Ben Seever on Growing Pains. Like Todd, Miller battled with alcohol addiction for years.
“I struggled every single day for the last 15 years. Honestly tried many ways to get sober until I found this program. Nothing worked. This was the savior for me,” said Miller in the same The Doctors episode.
Works for kleptos, gambling addicts
Incidentally, Naltrexone treats more than alcohol and opioid addiction. It has also been proven to curb kleptomaniacs’ compulsion to steal based on a study published on Science Daily.
For the study, University of Minnesota School of Medicine researchers recruited participants afflicted with kleptomania, a disorder characterized by one’s strong impulse to steal things. Participants of the study consisted of 25 men and women aged 17-75. Results revealed that those who took 117 mgs. of Naltrexone a day for eight weeks reported a decrease in stealing behavior as compared to participants on placebo.
According to the study, the drug worked by blocking the effects of “endogenous opiates” or endorphins, which the brain releases during stealing.
Another study, published on the journal of Biological Psychiatry and Science Direct, suggests that Naltrexone is effective in reducing symptoms of pathologic gambling. The study involves enrolling 45 patients in a double-blind Naltrexone and placebo comparison trial.
The Start Fresh Program targets alcohol and drug addiction on all fronts by eliminating the patient’s physiological and psychological cravings of opioids. Its core components include an outpatient Naltrexone implant procedure and psycho-social one-on-one coaching. The program has been proven to have an 85 percent success rate among participants, according to BioCoRx.
BioCoRx, Inc. is focused on designing and delivering cutting-edge addiction treatment and rehabilitation modalities. The company was formerly known as Fresh Start Private Management (OTCQB: CEYY). It is positioned to help thousands of Americans beat alcoholism and opioid addiction.
The Naltrexone implant is specially designed by BioCoRx, Inc. and is made from biodegradable materials. BioCoRx, Inc. owns the worldwide rights (except in Australia and New Zealand) to the implant.